Needham lowered the firm’s price target on Revolution Medicines (RVMD) to $62 from $68 but keeps a Buy rating on the shares. The firm is updating its model after the company closed its upsized ...
Mizuho analyst Vikram Malhotra lowered the firm’s price target on Ventas (VTR) to $68 from $71 and keeps an Outperform rating on the shares. The firm says that despite healthcare real estate ...
Image (c) Jamie Grill Photography/Getty Images Lowering your taxable income is a common concern for individuals and business owners. While the Tax Cuts and Jobs Act (TCJA) provided increased ...
TSE:CGY opened at C$48.50 on Wednesday. The company has a current ratio of 1.38, a quick ratio of 1.20 and a debt-to-equity ratio of 39.88. Calian Group has a 12 month low of C$42.88 and a 12 ...